drugset

drugset / Trial / NCT00799552

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552 ↗

Phase 2 Completed 232 enrolled Resolvyx Pharmaceuticals, Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.

Timeline

Start: 2008-11
Primary completion: 2009-05
Completion: 2009-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NAVAMEPENT	Small molecule	—	Other

Indications